Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

554
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
554
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

665
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
665
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

250
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
250
Glaucoma: Overview01:25

Glaucoma: Overview

740
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
740

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Infectious Choroiditis Subdivided into Its Diverse Pathophysiological Sub-Groups Is the Best-Known and Most Appropriate Nomenclature to Date for the Reclassification and Diagnosis of Former White Dot Entities.

Diagnostics (Basel, Switzerland)·2026
Same author

Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report.

The American journal of case reports·2026
Same author

The effect of improving cervical extension function on quality of life in patients with dropped head syndrome.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2026
Same author

Clinical performance of the multiplex solid-phase "Direct Strip PCR" for infectious uveitis: a multicenter diagnostic accuracy study.

Japanese journal of ophthalmology·2026
Same author

Tattoo-Associated Sarcoid-like Uveitis: A Multicenter Registry Study.

Biomedicines·2026
Same author

Necrotic-cell-activated macrophages drive an ERK-Bcl-xL survival pathway in osteoclasts and confer bisphosphonate resistance.

Biochemical and biophysical research communications·2026

Related Experiment Video

Updated: Sep 9, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K

Early prostaglandin E1 treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.

Hiroki Sano1, Ryoji Yanai2, Hirotaka Kondo1

  • 1Department of Ophthalmology, Tokushima Red Cross Hospital, Komatsushima, Japan.

Frontiers in Ophthalmology
|September 5, 2025
PubMed
Summary
This summary is machine-generated.

Early treatment with Prostaglandin E1 (PGE1) significantly improved vision in central retinal artery occlusion (CRAO) patients. This suggests PGE1 is a promising therapy for retinal ischemia emergencies.

Keywords:
central retinal artery occlusionneuroprotectionoptical coherence tomographyprostaglandin E1retinal ischemiavisual outcome

More Related Videos

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.9K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K

Related Experiment Videos

Last Updated: Sep 9, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.5K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.9K
Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.5K

Area of Science:

  • Ophthalmology
  • Vascular Medicine
  • Pharmacology

Background:

  • Central retinal artery occlusion (CRAO) is a critical condition causing sudden vision loss.
  • Current treatments for CRAO lack established efficacy.
  • Prostaglandin E1 (PGE1) possesses vasodilatory and cytoprotective qualities, indicating potential therapeutic value.

Purpose of the Study:

  • To evaluate the efficacy of early intravenous Prostaglandin E1 (PGE1) administration in improving visual outcomes for patients with central retinal artery occlusion (CRAO).
  • To compare the visual acuity and retinal structural changes in CRAO patients treated with PGE1 versus conventional therapy.

Main Methods:

  • A retrospective study comparing CRAO patients receiving intravenous PGE1 within 24 hours of symptom onset followed by oral administration.
  • Intravenous PGE1 was administered for 5 days.
  • Visual acuity and retinal parameters (maximal retinal thickness, central retinal thickness, arteriovenous diameters) were assessed and compared between the PGE1 and control groups.

Main Results:

  • The PGE1 group demonstrated significantly better best-corrected visual acuity at one month compared to the control group.
  • No significant differences in baseline retinal thickness (maximal retinal thickness, central retinal thickness) were observed between groups.
  • Baseline maximal retinal thickness in the PGE1 group was negatively correlated with one-month visual acuity. Retinal arteriovenous diameters remained unchanged post-treatment.

Conclusions:

  • Early administration of intravenous Prostaglandin E1 (PGE1) appears to enhance visual recovery in central retinal artery occlusion (CRAO) patients.
  • PGE1 shows potential as an effective treatment for acute retinal ischemia.
  • Further research is warranted to confirm these findings and establish PGE1's role in managing CRAO.